Zoetis: Cheap Valuation And Attractive Product Launch Pipeline [Seeking Alpha]
Zoetis Inc. Class A (ZTS)
Last zoetis inc. class a earnings: 2/13 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.zoetis.com
Company Research
Source: Seeking Alpha
ZTS targets new therapeutic white spaces—oncology, cardiology, and renal disease—minimizing risk and offering substantial first-mover advantages. The CKD monoclonal antibody for canine renal disease, launching in 2027, could unlock a $3–4 billion market with recurring revenue potential. Near-term headwinds are cyclical, not structural; as pipeline drugs launch and sentiment normalizes, ZTS should re-rate toward historical multiples. Oliver Rossi/DigitalVision via Getty Images Investment action I give a buy rating for Zoetis ( ZTS ) because of the upcoming product launches and a cheaper relative valuation vs. its closest peers. Once the near-term issues fade, which I expect them to eventually, the This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I
Show less
Read more
Impact Snapshot
Event Time:
ZTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZTS alerts
High impacting Zoetis Inc. Class A news events
Weekly update
A roundup of the hottest topics
ZTS
News
- What to Expect From Zoetis' Next Quarterly Earnings Report [Yahoo! Finance]Yahoo! Finance
- Zoetis (NYSE:ZTS) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d+)" rating to a "hold (c-)" rating.MarketBeat
- How New Institutional Interest and Vaccine Approvals Could Reshape Zoetis' (ZTS) Investment Narrative [Yahoo! Finance]Yahoo! Finance
- Zoetis (ZTS): Harnessing Growth with Minimum Rivalry [Yahoo! Finance]Yahoo! Finance
- ???????????????????? : ????????????????????????????·?????????????2033??61?3000???????????? [CNET News]CNET News
ZTS
Earnings
- 11/4/25 - Beat
ZTS
Sec Filings
- 1/12/26 - Form 4
- 1/12/26 - Form 4
- 1/12/26 - Form 4
- ZTS's page on the SEC website